H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $42 from $40 and keeps a Buy rating on the shares. The top-line results from the pivotal Phase 3 FURVENT trial are expected in early 2026, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma price target lowered to $33 from $40 at Citi
- ArriVent BioPharma Advances Cancer Therapeutics Pipeline
- Positive Growth Trajectory and Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Clinical Data and Strategic Development
- ArriVent Biopharma reports Q2 EPS (90c), consensus (71c)
- ArriVent Biopharma sees cash runway into mid-2027